AE1 ACE-031

ACE-031 is a soluble decoy receptor fusion protein constructed from the extracellular ligand-binding domain of Activin Receptor Type IIB (ActRIIB) fused to the Fc region of human IgG1. The ActRIIB ectodomain has nanomolar affinity for multiple TGF-β superfamily ligands that negatively regulate muscle mass, most notably myostatin (GDF-8), activin A, GDF-11, and BMP-9.

By sequestering these ligands before they can engage cell-surface ActRIIB receptors and activate the SMAD2/3 signaling pathway, ACE-031 effectively removes the brakes on muscle protein synthesis, resulting in significant increases in lean muscle mass. In Phase I/II clinical trials in healthy volunteers, ACE-031 produced dose-dependent increases in thigh muscle volume within weeks of administration. It has been studied in Duchenne muscular dystrophy, cancer cachexia, and other muscle-wasting conditions.

• ActRIIB ligand trap pharmacology and myostatin/activin sequestration
• Lean muscle mass anabolism and anti-catabolic signaling research
• TGF-β superfamily SMAD2/3 pathway inhibition studies
• Muscular dystrophy and cachexia preclinical models
• Skeletal muscle hypertrophy mechanisms and satellite cell activation
• Comparison with anti-myostatin antibodies and other muscle-building biologics

Dose levels referenced by the MVLabs peptide calculator, shown for research reference only:

ActRIIB decoy (myostatin pathway) studied at multi-week intervals.

Research reference only — not dosing guidance for human use. Use the calculator for other vials or volumes.

Supplied as a lyophilized powder. Store at 2–8 °C on receipt; protect from heat, light and moisture, and avoid excessive agitation. If reconstitution is required for laboratory work, use sterile technique — bacteriostatic water, or 0.6% acetic acid for low-solubility peptides. Protocols vary by research application.